PCM
CLRB icon

Prelude Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Prelude Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-434
Closed -$271K – 1571
2020
Q4 		$271K Buy
+434
New +$199K 0.01% 963

Other funds holding CLRB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Prelude Capital Management's CLRB Position: Q1 2021 in Review

Prelude Capital Management sold out of Cellectar Biosciences (CLRB) in Q1 2021, closing a stake of 434 shares — an estimated $271K sold.

Prelude Capital Management first reported a position in CLRB in Q4 2020 and held it in 1 quarter. The position peaked at $271K in Q4 2020. 44 funds tracked by Wall St. Rank hold CLRB as of Q1 2021.

  • Prelude Capital Management reported no remaining Cellectar Biosciences position as of Q1 2021 after selling out during the quarter.
  • Prelude Capital Management sold 434 Cellectar Biosciences shares in Q1 2021, an estimated $271K.
  • Prelude Capital Management first reported a position in Cellectar Biosciences in Q4 2020 and held it in 1 quarter.
  • Prelude Capital Management's Cellectar Biosciences position peaked at $271K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.